Resumen
Se denomina “Deterioro Cognitivo Leve” a un estado transicional entre los cambios cognitivos del envejecimiento normal y un estadio temprano de la demencia. En la actualidad, el constructo deterioro cognitivo leve (DCL) se reconoce como una condición patológica, no como un proceso normal asociado a la edad, y se utiliza específica- mente para referirse a un grupo de individuos que presentan cierto grado de déficit cognitivo cuya severidad resulta insuficiente para cumplir criterios de demencia ya que no presentan un compromiso esencial en las actividades de la vida diaria (1). Originalmente el MCI refería a un déficit de memoria en el contexto de funciones no-amnésicas preservadas (DCL amnésico) pero actualmente el término incluye déficits en otras funciones cognitivas más allá de la memoria. El DCL amnésico es posiblemente un estado precursor de la enfermedad de Alzheimer. Los datos neuropatológicos confirman esta transición del DCL amnésico a enfermedad de Alzheimer.
Citas
PETERSEN RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256:183-194.
REISBERG B, FERRIS SH, DE LEON MJ, ET AL. Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age- associated memory impairment and primary degen- erative dementia of the Alzheimer type. Drug Dev Res. 1988;15:101-114.
REISBERG B, FERRIS SH, DE LEON MJ, ET AL. The global deterioration scale for assessment of primay degenerative dementia. Am J Psychiatry. 1982; 139: 1136-1139.
MORRIS JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
MANES F, SERRANO C, CALCAGNO ML, CAR- DOZO J, HODGES J. Accelerated forgetting in sub- jects with memory complaints. A new form of Mild Cognitive Impairment? J Neurol. 2008;255:1067-70. Epub 2008 May 23.
ROBERTS RO, GEDA YE, KNOPMAN D, ET AL. The Mayo Clinic Study of Aging: design and sam- pling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30:58-69.
FARIAS ST, MUNGAS D, REED BR, HARVEY D, DECARLI C. Progression of mild cognitive impair- ment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66:1151-1157.
PETERSEN RC, THOMAS RG, GRUNDMAN M, ET AL. Alzheimer’s Disease Cooperative Study Group. Vitamin E and donepezil for the treat- ment of mild cognitive impairment. N Engl J Med. 2005;352:2379-2388.
FISCHER P, JUNGWIRTH S, ZEHETMAYER S, ET AL. Conversion from subtypes of mild cogni- tive impairment to Alzheimer dementia. Neurology. 2007;68:288-291.
TSCHANZ JT, WELSH-BOHMER KA, LYKET- SOS CG, ET AL. Cache County Investigators. Con- version to dementia from mild cognitive disorder: the Cache County Study. Neurology. 2006;67:229-234.
PETERSEN RC, SMITH GE, WARING SC, IVNIK RJ, TANGALOS EG, KOKMEN E. Mild cog- nitive impairment: clinical characterization and out- come. Arch Neurol. 1999; 56:303-308. 25.
AMIEVA H, LETENNEUR L, DARTIGUES J, ET AL. Annual rate and predictors of conversión to dementia in subjects presenting mild cognitive impair- ment criteria defined according to a population-based study. Dement Geriatr Cogn Disord. 2004; 18: 87-93.
AHMED S, MITCHELL J, ARNOLD R, NESTOR PJ, HODGES JR. Predicting rapid clinical progression in amnestic mild cognitive impairment. Dement Geriatr Cogn Disord. 2008;25:170-7.
GANGULI M, DODGE HH, SHEN C, ET AL. Mild cognitie impairment, amnestic type: an epide- miological study. Neurology. 2004; 63: 115-121.
VISSER PJ, SCHELTENS P, VERHEY FR, ET AL. Medial temporal lobe atrophy and memory dys- function as predictors for dementia in subjects with mild cognitive impairment. J Neurol. 1999;246:477- 485.
JACK CR JR, LOWE VJ, SENJEM ML, ET AL. 11C PiB and structural MRI provide complemen- tary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 2008;131:665-680.
FOX NC, SCAHILL RI, CRUM WR, ROSSOR MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology. 1999;52:1687- 1689.
APOSTOLOVA LG, DUTTON RA, DINOV ID, ET AL. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol. 2006; 63: 693-699.
MATTSSON N, ZETTERBERG H, HANSSON O, ET AL. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385-393.
OKELLO A, KOIVUNEN J, EDISON P, ET AL. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009; 8;73:754-60
JACK CR JR, LOWE VJ, WEIGAND SD, ET AL. Alzheimer’s Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain. 2009;132:1355-1365.
HANSSON O, ZETTERBERG H, BUCHHAVE P, LONDOS E, BLENNOW K, MINTHON L. Association between CSF biomarkers and incipi- ent Alzheimer’s disease in patients with mild cogni- tive impairment: a follow-up study. Lancet Neurol. 2006;5:228-234.
SHAW LM, VANDERSTICHELE H, KNAPIK- CZAJKA M ET AL. Alzheimer’s Disease Neuroimag- ing Initiative. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative sub- jects. Ann Neurol. 2009;65:403-413.
PETERSEN RC, SMITH GE, IVNIK RJ ET AL. Apolipoprotein E status as a predictor of the devel- opment of Alzheimer’s disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
AGGARWAL NT, WILSON RS, BECK TL, BIE- NIAS JL, BERRY-KRAVIS E, BENNETT DA. The apolipoprotein E 4 allele and incident Alzheimer’s disease in persons with mild cognitive impairment. Neurocase. 2005;11:3-7.
LOPEZ OL, JAGUST WJ, DULBERG C, ET AL. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol. 2003; 60:1394-9.
MITCHELL TW, MUFSON EJ, SCHNEIDER JA. Parahippocampal tau pathology in healthy aging, mild cognitive impairment and early Alzheimer´s disease. Ann Neurol. 2002; 51: 145-155.
BENNETT DA, SCHNEIDER JA, BIENIAS JL, EVANS DA, WILSON RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64:834-841.
DEKOSKY ST, IKONOMOVIC MD, STYREN SD, ET AL. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-55
LYKETSOS CG, LOPEZ O, JONES B, FITZPAT- RICK AL, BREITNER J, DEKOSKY S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascu- lar Health Study. JAMA. 2002;288:1475-1483.
GEDA YE, ROBERTS RO, KNOPMAN DS, ET AL. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging. Arch Gen Psychiatry. 2008; 65:1193-1198.
JEAN L, BERGERON ME, THIVIERGE S, SIMARD M. Cognitive intervention programs for individuals with mild cognitive impairment: system- atic review of the literatura. Am J Geriatr Psychiatry. 2010;18:281-296.
BELLEVILLE S. Cognitive training for persons with mild cognitive impairment. Int Psychogeriatr 2008; 20:57–66.
CLARE L, WOODS RT. Cognitive rehabilitation and cognitive training for early-stage Alzheimer’s dis- ease and vascular dementia. Cochrane Database Syst Rev 2003:CD003260.
VERGHESE J, LEVALLEY A, DERBY C, ET AL. Leisure activities and the risk of amnestic mild cogni- tive impairment in the elderly. Neurology. 2006;66:821- 827.
LAUTENSCHLAGER NT, COX KL, FLICKER L, ET AL. Effect of physical activity on cognitive func- tion in older adults at risk for Alzheimer disease: a randomized trial [published correction appears in JAMA. 2009;301:276]. JAMA. 2008;300: 1027-1037.
GEDA YE, ROBERTS RO, KNOPMAN DS, ET AL. Physical Exercise, Aging, and Mild Cognitive Impairment. Arch Neurol. 2010;67:80-86.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.